New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:25 EDTAZN, AZN, BMY, BMY, CLDX, CLDX, MRK, MRK, IMUC, IMUC, NWBO, NWBO, RHHBY, RHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Pharmaceuticals Analyst Fernandez and Biotech Analyst Liang, along with Key Opinion Leader Dr. David Reardon, discuss new developments in Glioblastoma (GBM) on an Analyst/Industry conference call. Relevant companies AZN, BMY, CLDX, MRK, IMUC, NWBO and RHHBY may be discussed on the Analyst/Industry conference call to be held on April 15 at 10 am.
News For AZN;BMY;CLDX;MRK;IMUC;NWBO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
08:19 EDTCLDXCelldex Rindo data looks like 'home run,' says Cowen
Subscribe for More Information
08:13 EDTBMYPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
08:10 EDTBMYBristol-Myers presents results from Phase IIIb AVERT trial at ACR
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT trial that investigated the use of Orencia plus methotrexate in biologic and MTX-na´ve citrullinated protein-positive early moderate to severe rheumatoid arthritis patients. These data were presented this week at the American College of Rheumatology 2014 annual meeting. Orencia is currently indicated in adults for moderate to severe RA. Orencia should not be administered with tumor necrosis factor antagonists and should not be used with other biologic RA drugs. One of the analyses looked at anti-CCP antibodies, which are a marker of RA and may contribute to disease progression. The analysis assessed the development of anti-CCP antibodies in patients with early rapidly progressing RA by measuring isotypes and the number of epitopes recognized after treatment with Orencia plus MTX, Orencia alone, or MTX alone. Results demonstrated Orencia plus MTX numerically reduced the concentrations of all CCP isotypes and the average number of epitopes recognized over one year of treatment more than Orencia alone or MTX alone. Over 12 months of treatment, 6.7 percent, 12.1 percent, and 7.8 percent of patients on Orencia plus MTX, Orencia alone, and MTX alone, respectively, experienced a serious adverse event and 1.7 percent, 4.3 percent and 2.6 percent led to discontinuation. Serious infections were observed in 0.8 percent of patients in the combination arm and 3.4 percent in the Orencia monotherapy arm. None of the patients in the MTX alone arm experienced a serious infection. Malignancies were reported in 0.8 percent, 1.7 percent, and 0 percent of patients in the Orencia + MTX, Orencia, and MTX arms, respectively. Additionally at ACR, investigators presented 12-month efficacy data from AVERT, including new results assessing the effect of Orencia on more clinically stringent remission criteria than DAS-defined remission, as well as new MRI data. Significantly more patients on Orencia plus MTX achieved the stringent clinical endpoint of Boolean-defined remission at 12 months.
07:16 EDTAZNMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:12 EDTCLDXCelldex data better than expected, says Cantor
Cantor believes that data from the Phase II trial of Celldex's rindopepimut in EGFRvIII-positive glioblastoma multiforme patients exceed expectations. The firm thinks the data is likely to trigger a turning point in the shares. Cantor keeps a $33 price target and Buy rating on the stock.
07:08 EDTAZNMedImmune presents positive Phase IIb data for mavrilimumab in RA
Subscribe for More Information
07:07 EDTAZNMedImmune presents new data in systemic lupus
Subscribe for More Information
06:43 EDTAZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:30 EDTRHHBYInovio, Roche terminate collaboration for INO-5150
Subscribe for More Information
November 16, 2014
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
13:26 EDTMRKMerck: KEYTRUDA showed superiority to chemotherapy for primary endpoint of PFS
Subscribe for More Information
13:07 EDTBMYBristol-Myers announces results from CheckMate -066 study
Subscribe for More Information
November 14, 2014
15:57 EDTCLDXCelldex to meet with FDA, propose accelerated approval filing, Feuerstein says
Subscribe for More Information
15:42 EDTCLDXCelldex sees significant survival benefit in Avastin-naive phase 2 trial
Subscribe for More Information
14:53 EDTRHHBY, AZN, MRK, BMYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
11:46 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
07:14 EDTAZN, BMYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:10 EDTIMUCImmunoCellular jpresents positive Phase II data for ICT-107
ImmunoCellular announces the presentation of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107. Consistent with prior data presentations in December 2013 and June 2014, the results demonstrate a statistically significant progression-free survival benefit, and a numeric overall survival benefit in ICT-107 treated patients compared to the control group. The ICT-107 treatment effect continues to be strongest in the pre-defined HLA-A2 subgroup of patients in which the MGMT methylated patients showed the largest treatment effect, with a significant PFS advantage over the control group, and continued potential for the OS advantage to move toward significance as more events occur. There were no differences in adverse events between the ICT-107 treated group and the control group. The company is utilizing all available information from the controlled phase II trial to design phase III testing in order to increase its probability of success, including the timing of randomization within the standard-of-care treatment these patients receive, in an attempt to limit the number of patients who are "early progressors" and unlikely to respond to therapy.
06:05 EDTBMYBristol-Myers to construct biologics manufacturing facility in Ireland
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use